Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Top Cited Papers
- 1 May 2005
- journal article
- clinical trial
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (5), 271-278
- https://doi.org/10.1016/s1470-2045(05)70101-7
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The cervical cancer epidemic that screening has prevented in the UKThe Lancet, 2004
- Treatment for Cervical Intraepithelial Neoplasia and Risk of Preterm DeliveryJAMA, 2004
- A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineVaccine, 2004
- Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy womenVaccine, 2004
- Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccineVaccine, 2004
- Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex AssayClinical and Vaccine Immunology, 2003
- Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle VaccineJournal of Virology, 2002
- Neutralization of Human Papillomavirus Type 11 (HPV‐11) by Serum from Women Vaccinated with Yeast‐Derived HPV‐11 L1 Virus‐like Particles: Correlation with Competitive Radioimmunoassay TiterThe Journal of Infectious Diseases, 2001
- Exact power and sample size for vaccine efficacy studiesCommunications in Statistics - Theory and Methods, 1998
- Human Papillomavirus Type 11 (HPV‐11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV‐11 Virus‐like Particles Expressed in YeastThe Journal of Infectious Diseases, 1997